Pseudomonas aeruginosa is an opportunistic microorganism with the ability to respond to a wide variety of environmental changes, exhibiting a high intrinsic resistance to a number of antimicrobial agents. This low susceptibility to antimicrobial substances is primarily due to the low permeability of its outer membrane, efflux mechanisms and the synthesis of enzymes that promote the degradation of these drugs.
INTRODUCTION

Pseudomonas
aeruginosa is a Gram-negative opportunistic pathogen, non-fermenting and, unable to produce energy for cell functioning (14) . Non-fermenting bacteria are ubiquitous in nature, particularly in soil and water, and on surfaces in contact with soil or water. In the hospital environment, these microorganisms can be isolated from other Gram-negative bacteria (13) .
However, bacterial resistance to -lactam antibiotics caused by low membrane permeability or efflux pumps is quite frequent for P. aeruginosa, Escherichia coli and Neisseria gonorrhoeae. Efflux mechanisms result in higher minimum inhibitory concentrations for penicillins, broad-spectrum cephalosporins, tetracyclins and fluoroquinolones (12, 30) .
Studies performed by Sentry (Antimicrobial Surveillance
Program) about the activity of broad-spectrum -lactam antibiotics against P. aeruginosa showed that about 17 to 34% of the bacterial samples were resistant to cefepime and ceftazidime (10, 24).
Since the bacterial outer membrane plays a major role in the permeability of antibiotics, the use of liposomal carriers is an interesting approach to enhance the antimicrobial activity of certain drugs (25) . The lipid bilayer of liposomes are able to fuse with the outer membrane of bacteria (8, 27) , altering the therapeutic index of a drug (20, 28) . Drug encapsulation into liposomes is an effective method to reduce the drug's toxicity, prolonging its circulation time after intravenous administration and enhancing its accumulation in the target site. These advantages can also improve the efficacy of antibiotics, not only for the treatment of resistant bacterial strains but also contributing to overcome bacterial resistance (4, 9, 15) .
In this work, liposomal formulations for cefepime and ceftazidime were prepared and characterized. The antibacterial effect of liposomal cefepime and ceftazidime against P.
aeruginosa ATCC 27853 and P. aeruginosa SPM-1 (clinical strain) was investigated by determining the Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) in a time-kill study.
MATERIALS AND METHODS
Chemicals
Cefepime was obtained from Alembic Limited, ceftazidime from Advan Pharma Chem Co. Ltd, soy phosphatidylcholine (PC) was from Lipoid, Gmb; cholesterol from Avanti Polar Lipids, -tocopherol was purchased from Sigma Co., all other chemicals and reagents were of analytical grade or superior. 
Microorganisms
Pseudomonas aeruginosa
Preparation of Liposomes
Liposomes were prepared by the lipid film hydration method. 40 mM of phosphatidylcholine (PC), 10 or 20 mM of cholesterol (Chol) and 0.04 mM of -tocopherol were dissolved in 2 mL of chloroform in a round bottom glass tube.
Chloroform was removed under a Nitrogen stream and a rotary Antimicrobial activity against P. aeruginosa 
Stability of liposomal formulations
Stability of liposomal formulations was determined in order to evaluate the rate of drug leakage from liposomes.
After the removal of the non-encapsulated drug, liposome dispersions were maintained at 4°C for 96 hours and at each 24 hours interval, samples were withdrawn for another step of separation in the sephadex column. The remaining amount of entrapped drug was determined by HPLC as described above.
Determination of the Minimum Inhibitory Concentration (MIC)
Antimicrobial activity of cefepime and of ceftazidime against Pseudomonas aeruginosa ATCC 27853 and P. 
RESULTS
Encapsulation Efficiency
The amount of encapsulated drug was 0.150 mg. Figures 1 and 2 show, Antimicrobial activity against P. aeruginosa respectively, the antimicrobial activity of free and liposomal ceftazidime, and free and liposomal cefepime against P.
Determination of MBC:
aeruginosa ATCC 27853, and figure 3 (23) were able to encapsulate 75.4% of cefoxitine. However, liposomes from that study had a mean diameter higher than 600 nm, which despite the larger aqueous internal volume; these vesicles exhibit a higher content leakage and tendency to agglomerate. Higher concentrations of cholesterol (>30 molar%) can completely eliminate membrane phase transition and fluidity (29) . In this work, a higher encapsulation efficiency and stability was obtained with liposome formulations using a molar ratio for cholesterol of 50 molar% in relation to PC.
Cefepime and ceftazidime leakage from liposomes was higher than that reported by Drulis-Kawa et al (7) respectively. This 50% reduction was probably due to the interaction between liposomes and bacterial cells by a fusion mechanism as previously reported (1, 4, 20) , which is capable of increasing the intracellular concentration of the drug, reducing the bacteria's ability to develop resistance. Other Antimicrobial activity against P. aeruginosa researchers showed that liposomal encapsulation was able to protect piperacylin from hydrolysis promoted by bacterial β-lactamase, which was probably due to the localization of the drug in the interior of the liposome where β-lactamase cannot penetrate (19) .
Results from this work are in agreement with those found 
